Opthea Media, page-3

Amazing?

It's a Phase 2 trial, interim analysis
Efficacy
Injection-Free Rates: A significant portion of patients remained injection-free over the 26-week period, highlighting the potential of Ixo-vec to reduce the treatment burden associated with frequent ocular injections.
Visual Acuity: Patients maintained stable visual acuity, suggesting that Ixo-vec effectively controls the progression of wet AMD.

Where is the improved vision outcome? Without this how can it hold best-in-class treatment for wet AMD ?

Sozinibercept has the potential to improve vision for millions of patients with wet AMD.
If successful OPT could be heading towards new standard of care with best-in-class, is it not?